FEMASYS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
FEMASYS INC. - More news...
FEMASYS INC. - More news...
- Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
- Femasys Expands Commercial Management Team with Addition of Experienced New Hires
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
- Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
- Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
- Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
- Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
- Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
- Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
- Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
- Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
- Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
- Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
- Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
- Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
- Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
- Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
- Femasys Inc. EU MDR Final Audit Successfully Completed
- Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
- Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
- Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
- Femasys Inc. MDSAP Surveillance Audit Successfully Completed
- Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
- Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
- Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
- Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Femasys Inc. Obtains Medical Device Establishment License from Health Canada
- Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
- Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
- Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
